Whitepaper: iPSC manufacturing for drug discovery
Posted: 13 July 2020 | Ncardia | No comments yet
Controlled manufacturing of hiPSC-derived cardiomyocytes in stirred-tank bioreactors enabling high-throughput phenotypic screening.
The lack of physiologically-relevant cell-based assays is an obstacle in drug development. Introducing human disease biology early in drug development could make it more effective. However, human primary tissues are rarely available in quantities sufficient for HTS. Although hiPSCs are suitable for disease modeling, the challenge of industrial scale manufacturing from different hiPSC sources has long remained. Here we describe how we enabled the production of batches of billions of cells.
Related content from this organisation
- Whitepaper: Advancing drug discovery for neurodegenerative diseases
- Right model, right complexity: using in vitro human disease cell models in drug discovery
- Targeting tau – chasing a treatment for Alzheimer’s
- Cellistic and Celyad Oncology announce GMP cell therapy manufacturing operations transaction
- Drug Target Review Neuroscience ebook 2022
Hit-to-Lead, Imaging, Screening, Stem Cells, Targets